

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/825,584	04/04/2001	Robert Akita	obert Akita P1003R1C1D1		
7	7590 07/02/2002				
Attn: Wendy M. Lee Genentech; Inc. 1 DNA Way			EXAMINER		
			YAEN, CHRISTOPHER H		
South San Fran	ncisco, CA 94080-4990		ART UNIT	PAPER NUMBER	
			1642	٣	
			DATE MAILED: 07/02/2002	/	

Please find below and/or attached an Office communication concerning this application or proceeding.

		A	No.	Annlicant/a)					
Office Action Summary		Application No. Applicant(s)							
		09/825,584		AKITA ET AL.					
		Examiner		Art Unit					
		Christopher		1642					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status									
1)⊠	1) Responsive to communication(s) filed on <u>04 April 2001</u> .								
2a) <u></u> ☐	This action is <b>FINAL</b> . 2b)⊠ Th	his action is n	on-final.						
3)	Since this application is in condition for allows closed in accordance with the practice under	ance except	for formal matters, pr	osecution as to th	ne merits is				
Dispositi	on of Claims	Lx parte Qu		00 0.0. 2.0.					
4)⊠	4)⊠ Claim(s) <u>1-51</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.									
6)□	6) Claim(s) is/are rejected.								
7)	Claim(s) is/are objected to.								
8) Claim(s) 1-51 are subject to restriction and/or election requirement.									
	on Papers	1							
,	The specification is objected to by the Examine		I I I I bodha Foa	i					
10)[_]	The drawing(s) filed on is/are: a) ☐ acce								
111	Applicant may not request that any objection to the proposed drawing correction filed on								
11)				voa by the Exami					
If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a) ☐ All b) ☐ Some * c) ☐ None of:									
1. Certified copies of the priority documents have been received.									
	2. Certified copies of the priority documents have been received in Application No								
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>									
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.									
Attachment(s)									
2) Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)		· ==	r (PTO-413) Paper No Patent Application (P1					

Art Unit: 1642

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1,3-10, 12-19, and 21, drawn to an antibody that binds and reduces or increases heregulin-induced formation and a cell linea kit, classified in class 424, subclass 130.1, for example.
  - II. Claims 2 and 11, drawn to an antibody that binds and increases the binding affinity of heregulin, classified in class 424, subclass 130.1.
  - III. Claim 20, drawn to a method of determining of ErbB3 protein the presence, classified in class 436, subclass 501.
  - IV. Claims 22-37, 40-41,44-45, and 48-49, drawn to nucleic acid sequence, vectors, and host cells, and , classified in class 536, subclass 23.1, for example.
  - V. Claims 38-39, 42-43, 46-47, and 50-51, drawn to method of making an antibody, classified in class 435, subclass 70.1.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I, II and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions differ one from the other because the invention are chemically, structurally, and functionally different.

Art Unit: 1642

- 3. Inventions III and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions differ one from the other because the method are drawn to processes requiring different steps, have different outcomes and have different effects.
- 4. Inventions V and I, II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the method of making the antibodies can be used to make other antibodies unrelated to the antibody of the instant invention.
- 5. Inventions I-II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the method of group III can be used to detect proteins using a different antibody than the ones in group I and II.
- 6. Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of

Art Unit: 1642

operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions differ one form the other because the method of detecting is drawn to a antibody, which is not used by the nucleic acids of group IV.

- 7. Because these inventions are distinct for the reasons given above and the search required for the different groups are not overlapping and are not coextensive, restriction for examination purposes as indicated is proper.
- 8. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 9. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 703-305-3586. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-

Art Unit: 1642

308-4242 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Christopher Yaen Art Unit 1642 July 1, 2002

> ANTHONY C. CAPUTA SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600